MedTrace Logo

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

NCT04696042 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2025-01-28

No results posted yet for this study

Summary

Lanreotide Autogel® has been established as a standard of care for patients with locally advanced or metastatic GEP-NETs based on the success of CLARINET trial. However, only few patients with Asian ethnicity were included in the trial.

According to the nationwide comprehensive study of patients with GEP-NET in Korea, hindgut primary NETs(Rectal) occured more frequently than western countries. However, small intestine or lung primary NET is relatively rare compared with western countries.1) Considering the clinical characteristics of GEP-NETs are distinct between the patients in Asian and Western countries, further evaluation on the efficacy and safety of Lanreotide Autogel® in Asian patients with GEP-NETs is needed.

Conditions

Interventions

DRUG

Lanreotide autogel

Lanreotide autogel 90-120 mcg, every 4 weeks

Sponsors & Collaborators

  • Samsung Medical Center

    collaborator OTHER

  • Seoul St. Mary's Hospital

    collaborator OTHER

  • Severance Hospital

    collaborator OTHER

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Changhoon Yoo · Asan Medical Center

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2024-01-30
Completion
2025-01-27

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04696042 on ClinicalTrials.gov